Michael Musk
Overview
Explore the profile of Michael Musk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boan P, Jamboti J, Musk M, Lavender M, Wrobel J, Lee F, et al.
Intern Med J
. 2024 Mar;
54(4):678-681.
PMID: 38450913
We transplanted six solid organs from three hepatitis C virus (HCV) polymerase chain reaction (PCR)-positive donors during 2018-2023. Recipients were treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir for 4-12 weeks, with all...
2.
Law L, Lo W, House C, Rawlins M, Boan P, Musk M
Intern Med J
. 2023 Dec;
54(2):234-241.
PMID: 38064419
Background: Western Australia (WA) serves as a unique global case study on the impact of coronavirus disease 2019 (COVID-19) on an isolated, prepared and highly vaccinated population. This study builds...
3.
House C, Rawlins M, Dyer J, Boan P, Musk M
Intern Med J
. 2023 Jul;
53(9):1548-1555.
PMID: 37493390
Background: Western Australia (WA) was in a unique position to experience coronavirus disease 2019 (COVID-19) in a highly vaccinated and geographically isolated population. Aim: To describe the COVID-19 Omicron experience...
4.
Wigston C, Lavender M, Long R, Sankhesara D, Ching D, Weaire-Buchanan G, et al.
Open Forum Infect Dis
. 2023 Jun;
10(6):ofad263.
PMID: 37323424
Hyperammonemia syndrome (HS) is a life-threatening condition occurring in solid organ transplant patients, affecting primarily lung recipients, and is associated with and/or spp infection. The organ donor was a young...
5.
Boan P, Pang S, Mowlaboccus S, Wrobel J, Musk M, Lavender M, et al.
Transplantation
. 2022 Jan;
106(2):e169-e171.
PMID: 35100230
No abstract available.
6.
Whitmore T, Yaw M, Lavender M, Musk M, Boan P, Wrobel J
Transpl Infect Dis
. 2021 Feb;
23(4):e13587.
PMID: 33590676
Antifungal prophylaxis remains a mainstay of lung transplantation, given invasive fungal infection is a common and serious complication after lung transplantation. Choice of systemic agent to prevent invasive fungal infection...
7.
Ling K, Garratt L, Banerjee B, Lavender M, Wrobel J, Musk M, et al.
Transplantation
. 2020 Jan;
104(6):1166-1176.
PMID: 31985728
Background: Dysregulated airway epithelial repair following injury is a proposed mechanism driving posttransplant bronchiolitis obliterans (BO), and its clinical correlate bronchiolitis obliterans syndrome (BOS). This study compared gene and cellular...
8.
Van Raemdonck D, Keshavjee S, Levvey B, Cherikh W, Snell G, Erasmus M, et al.
J Heart Lung Transplant
. 2019 Nov;
38(12):1235-1245.
PMID: 31777330
Background: This study aimed to examine intermediate-term outcomes of lung transplantation (LTx) recipients from donors after circulatory death (DCD). Methods: We examined the International Society for Heart and Lung Transplantation...
9.
Ling K, Hillas J, Lavender M, Wrobel J, Musk M, Stick S, et al.
Respirology
. 2019 Apr;
24(12):1212-1219.
PMID: 30989728
Background And Objective: Human rhinovirus (RV) is a common upper and lower respiratory pathogen in lung allograft recipients causing respiratory tract exacerbation and contributing towards allograft dysfunction and long-term lung...
10.
Chang A, Musk M, Lavender M, Wrobel J, Yaw M, Lawrence S, et al.
Transpl Infect Dis
. 2019 Mar;
21(3):e13085.
PMID: 30925010
Background: Invasive fungal infections (IFI) are common after lung transplantation with reported incidence of 8.1% to 16% at 12 months post-transplant, and 3-month all-cause mortality after IFI of 21.7%. Methods:...